|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.04 USD | -0.84% |
|
+0.65% | -27.89% |
| 07-31 | Mizuho Trims Price Target on Tarsus Pharmaceuticals to $98 From $100, Keeps Outperform Rating | MT |
| 07-16 | RxSight Names Aziz Mottiwala as CEO | MT |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 2,540 | - | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | -26.92% | - | - |
| Enterprise Value (EV) | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 2,540 | 2,540 | 2,540 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | -26.92% | 0% | 0% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -26.7x | 23.8x | 11.8x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -0.7x | -0x | 0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 3.56x | 2.82x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.56x | 2.82x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -26.5x | 18.1x | 6.39x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -2.208 | 2.485 | 5.01 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 714.2 | 900.3 | - |
| EBITDA | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | - | - | - |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -96.03 | 140.6 | 397.3 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -98.78 | 82.72 | 321.6 |
| Net Debt | - | - | -198.3 | -222.5 | - | - | - | - |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 59.04 | 59.04 | 59.04 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,024 | - | - |
| Announcement Date | 14/03/22 | 13/03/23 | 27/02/24 | 25/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -26.75x | - | - | -.--% | 2.54B | |
| 18.09x | 4.1x | 9.64x | 0.51% | 76.15B | |
| 22.95x | 4.92x | 14.38x | 0.65% | 48.89B | |
| 36.16x | 12.36x | 23.52x | -.--% | 47.83B | |
| -46.27x | 3.25x | 9.61x | 3.29% | 41.37B | |
| 37.23x | 3.36x | 12.07x | -.--% | 29.99B | |
| 55.01x | 3.36x | 26.05x | -.--% | 24.23B | |
| -6.3x | 8.96x | -5.6x | -.--% | 21.89B | |
| 63.91x | 6.11x | 41.98x | -.--% | 19.25B | |
| 24.69x | 5.29x | 13.78x | -.--% | 17.14B | |
| Average | 17.87x | 5.75x | 16.16x | 0.45% | 32.93B | |
| Weighted average by Cap. | 18.87x | 5.71x | 14.92x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
